Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (EUCTR2026-000241-89-Outside-EU/EEA) titled 'Study of monoclonal antibody nirsevimab against Respiratory Syncytial Virus (RSV) in participants up to 24 months of age in India' on Oct. 4.
Study Type: Interventional clinical trial of medicinal product
Study Design:
Controlled: no Randomised: Open: yes Single blind: Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 1
Primary Sponsor: Sanofi Winthrop Industrie
Condition:
RSV immunization
MedDRA version: 21.1
Level: PT
Classification code 10061603
Term: ...